MedTrace Logo

Erythropoietin Gel as an Adjunct to Xenograft in the Surgical Management of Intrabony Periodontal Defects

NCT05360511 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2024-01-16

No results posted yet for this study

Summary

The aim of the study is to evaluate the use of erythropoietin gel as an adjunct to xenograft in the surgical management of intrabony periodontal defects.

Conditions

  • Periodontal Bone Loss

Interventions

DRUG

particulate xenograft + erythropoietin gel.

1. Surgical sites will be anaesthetized using local anaesthesia. 2. Intrasulcular incision will be done in the periodontal pocket as close as possible to the tooth surface with the deepest point being the alveolar crest. 3. The incisions will be extended to the mesial papilla of the tooth before the defect and the distal papilla of the tooth after the defect. 4. Both buccal and lingual/palatal mucoperiosteal flaps will be raised using blunt dissection. 5. Mechanical debridement of the infected tissue from the intrabony defect and root debridement will be done using Gracey curettes. * In Group A (test group): Particulate xenograft will be mixed with EPO gel and applied to fill the whole defect.

COMBINATION_PRODUCT

particulate xenograft

* All surgeries will be performed by the same operator as follows: 1. Surgical sites will be anaesthetized using local anaesthesia. 2. Intrasulcular incision will be done in the periodontal pocket as close as possible to the tooth surface with the deepest point being the alveolar crest. 3. The incisions will be extended to the mesial papilla of the tooth before the defect and the distal papilla of the tooth after the defect. 4. Both buccal and lingual/palatal mucoperiosteal flaps will be raised using blunt dissection. 5. Mechanical debridement of the infected tissue from the intrabony defect and root debridement will be done using Gracey curettes. * In Group B (control group): Particulate xenograft will be applied to fill the whole defect.

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Ahmed Amr, Professor · Ain Shams University

  • yasmin El Sayed, lecturer · Ain Shams University

  • Mahmoud Mousa, lecturer · MSA University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2023-09-01
Completion
2023-10-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05360511 on ClinicalTrials.gov